Eli Lilly and Co

Eli Lilly’s obesity pill will rival Novo Nordisk’s oral Wegovy drug

by
Eli Lilly’S Obesity Pill Will Rival Novo Nordisk’S Oral Wegovy Drug

Eli Lilly’s Obesity Pill Orforglipron Challenges Novo Nordisk’s Oral Wegovy in Weight-Loss Market Race August 24, 2025 The obesity drug market, projected to surpass $73 billion by 2034, is witnessing a fierce competition between pharmaceutical giants Eli Lilly and Novo Nordisk. Eli Lilly’s oral GLP-1 receptor agonist, orforglipron, is emerging as a significant rival to … Read more

Eli Lilly to build $5 billion Virginia manufacturing facility

by
Eli Lilly To Build Billion Virginia Manufacturing Facility

Eli Lilly’s $5 Billion Bet on Virginia: A Game-Changer for U.S. Drug Manufacturing In a bold move to fortify America’s pharmaceutical backbone amid looming trade tensions and surging demand for cutting-edge therapies, Eli Lilly and Company announced plans on September 16, 2025, to invest $5 billion in a state-of-the-art manufacturing facility in Goochland County, Virginia—just … Read more

Close